Avadel Pharmaceuticals plc
AVDLNASDAQHealthcare
$21.64
+$0.00(+0.00%)
Market Cap$2.1B
P/E Ratio—
52W High$23.57
52W Low$6.38
Avadel Pharmaceuticals plc (AVDL) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · AVDL · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2024-12 | 2023-12 | 2022-12 | 2021-12 | 2020-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.17B | $0.03B | $0.00B | $0.00B | $0.02B |
| Cost of Revenue | $0.02B | $0.00B | $0.00B | $0.00B | $0.01B |
| Gross Profit | $0.15B | $0.03B | $0.00B | $0.00B | $0.02B |
| Gross Margin %(computed) | 90.97% | 96.97% | — | — | 74.29% |
| Operating Expenses | |||||
| R&D Expenses | $0.02B | $0.01B | $0.02B | $0.02B | $0.02B |
| G&A Expenses | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Total Operating Expenses | $0.20B | $0.16B | $0.10B | $0.09B | $0.01B |
| Operating Income | ($0.04B) | ($0.14B) | ($0.10B) | ($0.09B) | $0.01B |
| Operating Margin %(computed) | -25.07% | -492.97% | — | — | 26.04% |
| Interest Income | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Interest Expense | $0.01B | $0.01B | $0.01B | $0.01B | $0.01B |
| Income Before Tax | ($0.05B) | ($0.16B) | ($0.11B) | ($0.09B) | ($0.01B) |
| Income Tax Expense | ($0.00B) | ($0.00B) | $0.03B | ($0.02B) | ($0.01B) |
| Net Income | ($0.05B) | ($0.16B) | ($0.14B) | ($0.08B) | $0.01B |
| Net Margin %(computed) | -28.87% | -573.17% | — | — | 31.47% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-0.51 | $-2.00 | $-2.29 | $-1.32 | $0.13 |
| Wtd Avg Shares | 0.10B | 0.08B | 0.06B | 0.06B | 0.05B |
| EBITDA | ($0.04B) | ($0.15B) | ($0.10B) | ($0.08B) | $0.01B |
| EBITDA Margin %(computed) | -21.03% | -533.29% | — | — | 42.99% |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · B
Explore more Avadel Pharmaceuticals plc data
About Avadel Pharmaceuticals plc (AVDL) Income Statement
Avadel Pharmaceuticals plc (AVDL) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2024, AVDL reported revenue of $0.17B, gross profit of $0.15B (gross margin 90.97%), and net income of ($0.05B) — a net profit margin of -28.87%.
Frequently asked questions
AVDL · 4 questionsAvadel Pharmaceuticals plc (AVDL) reported revenue of $0.17B for 2024, up 504.8% year-over-year.
AVDL revenueAVDL salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08